<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01286688</url>
  </required_header>
  <id_info>
    <org_study_id>01361</org_study_id>
    <nct_id>NCT01286688</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Under Fasting Conditions</brief_title>
  <official_title>Randomized, 2-way Crossover Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg and Lamisil® 250 mg Tablets in Healthy Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the rate and extent of absorption of terbinafine&#xD;
      hydrochloride 250 mg tablets versus Lamisil® 250 mg tablets administered as 1 x 250 mg tablet&#xD;
      under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, 2-way crossover, bioequivalence study of Terbinafine hydrochloride 250 mg tablets&#xD;
      and Lamisil® 250 mg Tablets administered as 1 x 250 mg tablet in healthy subjects under&#xD;
      fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">March 2002</completion_date>
  <primary_completion_date type="Actual">February 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence study based on Cmax parameter</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Fasting</condition>
  <arm_group>
    <arm_group_label>Terbinafine Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Terbinafine Hydrochloride Tablets, 250 mg of Dr.Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamisil® 250 mg Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lamisil® 250 mg Tablets of Novartis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbinafine Hydrochloride Tablets, 250 mg</intervention_name>
    <description>Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.</description>
    <arm_group_label>Lamisil® 250 mg Tablets</arm_group_label>
    <arm_group_label>Terbinafine Hydrochloride</arm_group_label>
    <other_name>Lamisil® 250 mg Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects enrolled in this study will be members of the community at large. The&#xD;
             recruitment advertisements may be done using different media (e.g. radio, newspaper,&#xD;
             Anapharm Web site, Anapharm volunteers' data base). ---Subjects must meet all of the&#xD;
             following criteria in order to be included in the study:&#xD;
&#xD;
          -  Subjects will be females and/or males, smokers and/or non-smokers, 18 years of age and&#xD;
             older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects to whom any of the following applies will be excluded from the study:&#xD;
&#xD;
          -  Clinically significant illnesses within 4 weeks of the administration of study&#xD;
             medication.&#xD;
&#xD;
          -  Clinically significant surgery within 4 weeks prior to the administration of the study&#xD;
             medication.&#xD;
&#xD;
          -  Any clinically significant abnormality found during medical screening.&#xD;
&#xD;
          -  Any reason which, in the opinion of the medical sub-investigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
&#xD;
          -  Abnormal laboratory tests judged clinically significant.&#xD;
&#xD;
          -  Positive urine drug screen at screening.&#xD;
&#xD;
          -  Positive testing for hepatitis B, hepatitis C or HIV at screening.&#xD;
&#xD;
          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood&#xD;
             pressure lower than 90 or over 140 mmHg, or diastolic blood pressure lower than 50 or&#xD;
             over 90 mm Hg; or heart rate less than 50 bpm) at screening.&#xD;
&#xD;
        Subjects with BMI ≥ 30.0.&#xD;
&#xD;
          -  History of significant alcohol abuse within six months of the screening visit or any&#xD;
             indication of the regular use of more than two units of alcohol per day (1 Unit = 150&#xD;
             mL of wine or 360 mL of beer or 45 mL of alcohol 40%).&#xD;
&#xD;
          -  History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana)&#xD;
             within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine&#xD;
             (PCP) and crack) within 1 year of the screening visit.&#xD;
&#xD;
          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the&#xD;
             medical sub-investigator, contraindicates the subjects participation in this study.&#xD;
&#xD;
          -  History of allergic reactions to terbinafine hydrochloride or other related drugs&#xD;
             (e.g.naftifine).&#xD;
&#xD;
          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of&#xD;
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids,&#xD;
             rifampin/rifabutin;examples of inhibitors: antidepressants, cimetidine, diltiazem,&#xD;
             erythromycin,ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine), use of&#xD;
             an investigational drug or participation in an investigational study within 30 days&#xD;
             prior to administration of the study medication.&#xD;
&#xD;
          -  Use of prescription medication within 14 days prior to administration of study&#xD;
             medication or over-the-counter products (including natural products, vitamins, garlic&#xD;
             as supplement)within 7 days prior to administration of study medication, except for&#xD;
             topical products without systemic absorption or oral contraceptives.&#xD;
&#xD;
          -  Subjects who have a depot injection or an implant of any drug (except for depot&#xD;
             injection or implant used as method of contraception) 3 months prior to administration&#xD;
             of study medication.&#xD;
&#xD;
          -  Subjects with a history of any previous liver disease.&#xD;
&#xD;
        Donation of plasma (500 mL) within 7 days. Donation or loss of whole blood prior to&#xD;
        administration of the study medication as follow:&#xD;
&#xD;
          -  less than 300 mL of whole blood within 30 days or&#xD;
&#xD;
          -  300 mL to 500 mL of whole blood within 45 days or&#xD;
&#xD;
          -  more than 500 mL of whole blood within 56 days. •Smoking more than 25 cigarettes per&#xD;
             day.&#xD;
&#xD;
        Additional exclusion criteria for females only:&#xD;
&#xD;
          -  Breast-feeding subjects.&#xD;
&#xD;
          -  Positive urine pregnancy test at screening (performed on all females).&#xD;
&#xD;
          -  Female subjects of childbearing potential who have had unprotected sexual intercourse&#xD;
             with any non-sterile male partner (i.e. male who has not been sterilized by vasectomy&#xD;
             for at least 6 months) within 14 days prior to study drug administration. The&#xD;
             acceptable methods of contraception are:&#xD;
&#xD;
               -  Condom + spermicide&#xD;
&#xD;
               -  Diaphragm + spermicide&#xD;
&#xD;
               -  Intrauterine contraceptive device (placed at least 4 weeks prior to study drug&#xD;
                  administration)&#xD;
&#xD;
               -  oral contraceptives (starting at least 4 weeks prior to study drug&#xD;
                  administration)&#xD;
&#xD;
               -  Implant (e.g. Norplant®) (starting at least 4 weeks prior to study drug&#xD;
                  administration)&#xD;
&#xD;
               -  Depot injection of a progestogen drug (e.g. Depo-Provera®) (starting at least 4&#xD;
                  weeks prior to study drug administration)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Bicrell</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Quebec</city>
        <zip>GIV 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>January 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2011</study_first_posted>
  <last_update_submitted>January 10, 2012</last_update_submitted>
  <last_update_submitted_qc>January 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2012</last_update_posted>
  <responsible_party>
    <name_title>Dr. Ramakrishna Bangaru/Assistant Manager</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>crossover</keyword>
  <keyword>Terbinafine hydrochloride</keyword>
  <keyword>Fasting</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terbinafine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

